Primary mucosal and acral melanomas exhibit a lower frequency of activating BRAF mutations, with mutations in KIT and NRAS predominating.16 Identification of specific KIT gene mutations is essential to determine the sensitivity to KIT-inhibitor therapy (imatinib or nilotinib). The gene discussed is BRAF; the disease is acral lentiginous melanoma.